Arcus Net Income Per Share vs Price To Sales Ratio Analysis

RCUS Stock  USD 17.16  0.26  1.49%   
Arcus Biosciences financial indicator trend analysis is way more than just evaluating Arcus Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcus Biosciences is a good investment. Please check the relationship between Arcus Biosciences Net Income Per Share and its Price To Sales Ratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.

Net Income Per Share vs Price To Sales Ratio

Net Income Per Share vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcus Biosciences Net Income Per Share account and Price To Sales Ratio. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Arcus Biosciences' Net Income Per Share and Price To Sales Ratio is 0.57. Overlapping area represents the amount of variation of Net Income Per Share that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Arcus Biosciences, assuming nothing else is changed. The correlation between historical values of Arcus Biosciences' Net Income Per Share and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income Per Share of Arcus Biosciences are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Net Income Per Share i.e., Arcus Biosciences' Net Income Per Share and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.57
Relationship DirectionPositive 
Relationship StrengthWeak

Net Income Per Share

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Arcus Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Arcus Biosciences sales, a figure that is much harder to manipulate than other Arcus Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.
Most indicators from Arcus Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcus Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.At this time, Arcus Biosciences' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 6.3 M in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (4.36).
 2021 2022 2023 2024 (projected)
Interest Income657K16M41M43.1M
Net Interest Income397K14M39M41.0M

Arcus Biosciences fundamental ratios Correlations

0.910.970.990.920.930.85-0.21-0.730.850.880.860.790.760.920.670.950.860.980.90.720.530.990.950.890.68
0.910.940.860.970.940.65-0.42-0.920.90.860.660.560.740.920.380.90.90.910.960.890.220.920.840.730.6
0.970.940.930.910.930.72-0.38-0.820.950.910.720.620.850.970.480.960.950.960.930.760.410.980.880.780.71
0.990.860.930.880.920.85-0.23-0.670.810.890.850.80.770.90.70.920.830.940.880.650.630.950.910.860.69
0.920.970.910.880.960.79-0.28-0.880.80.780.790.710.660.840.560.910.80.940.950.920.310.940.90.850.61
0.930.940.930.920.960.76-0.37-0.880.830.810.750.680.770.880.530.930.860.90.990.860.440.920.850.80.71
0.850.650.720.850.790.760.14-0.440.470.560.990.990.460.580.940.740.470.850.680.580.690.820.90.980.48
-0.21-0.42-0.38-0.23-0.28-0.370.140.58-0.58-0.520.210.28-0.71-0.460.39-0.37-0.56-0.13-0.45-0.34-0.03-0.20.050.13-0.42
-0.73-0.92-0.82-0.67-0.88-0.88-0.440.58-0.82-0.69-0.42-0.32-0.69-0.79-0.13-0.84-0.83-0.73-0.93-0.94-0.06-0.76-0.63-0.55-0.66
0.850.90.950.810.80.830.47-0.58-0.820.930.470.360.90.970.20.870.980.820.860.670.270.860.70.550.64
0.880.860.910.890.780.810.56-0.52-0.690.930.560.480.880.960.350.860.930.820.820.560.440.850.720.580.65
0.860.660.720.850.790.750.990.21-0.420.470.560.990.410.590.940.730.480.870.660.570.630.840.930.980.44
0.790.560.620.80.710.680.990.28-0.320.360.480.990.340.50.980.650.370.790.580.490.680.760.870.950.38
0.760.740.850.770.660.770.46-0.71-0.690.90.880.410.340.860.230.780.880.680.780.50.520.730.540.460.64
0.920.920.970.90.840.880.58-0.46-0.790.970.960.590.50.860.340.920.980.890.90.670.360.920.790.650.71
0.670.380.480.70.560.530.940.39-0.130.20.350.940.980.230.340.510.210.670.420.310.740.620.760.880.29
0.950.90.960.920.910.930.74-0.37-0.840.870.860.730.650.780.920.510.890.930.940.790.480.940.860.80.85
0.860.90.950.830.80.860.47-0.56-0.830.980.930.480.370.880.980.210.890.830.890.680.270.870.710.560.73
0.980.910.960.940.940.90.85-0.13-0.730.820.820.870.790.680.890.670.930.830.870.760.431.00.980.920.63
0.90.960.930.880.950.990.68-0.45-0.930.860.820.660.580.780.90.420.940.890.870.890.360.90.80.740.73
0.720.890.760.650.920.860.58-0.34-0.940.670.560.570.490.50.670.310.790.680.760.890.040.770.720.680.55
0.530.220.410.630.310.440.69-0.03-0.060.270.440.630.680.520.360.740.480.270.430.360.040.430.420.550.47
0.990.920.980.950.940.920.82-0.2-0.760.860.850.840.760.730.920.620.940.871.00.90.770.430.960.890.66
0.950.840.880.910.90.850.90.05-0.630.70.720.930.870.540.790.760.860.710.980.80.720.420.960.960.55
0.890.730.780.860.850.80.980.13-0.550.550.580.980.950.460.650.880.80.560.920.740.680.550.890.960.51
0.680.60.710.690.610.710.48-0.42-0.660.640.650.440.380.640.710.290.850.730.630.730.550.470.660.550.51
Click cells to compare fundamentals

Arcus Biosciences Account Relationship Matchups

Arcus Biosciences fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets203.1M772.3M1.6B1.3B1.1B767.6M
Other Current Liab1.5M31.4M52.0M73M65M68.3M
Total Current Liabilities22.7M121.7M166.1M193M184M99.4M
Total Stockholder Equity163.8M502.3M841.5M657M462M428.3M
Other Liab16.6M133.1M467.5M378M434.7M456.4M
Net Tangible Assets163.8M502.3M841.5M657M755.6M793.3M
Property Plant And Equipment Net9.3M23.6M137.4M35M51M39.5M
Net Debt(57.9M)(158.2M)(31.0M)(86M)(116M)(121.8M)
Retained Earnings(205.3M)(328.2M)(275.4M)(542M)(849M)(806.6M)
Accounts Payable4.7M15.7M10.3M20M17M10.8M
Cash57.9M173.4M147.9M206M127M130.2M
Non Current Assets Total10.4M37.2M910.6M278M264M211.7M
Non Currrent Assets Other872K7.2M591.2M114M106M113.0M
Other Assets1.1M25.7M10.7M14M16.1M8.5M
Cash And Short Term Investments188.3M735.1M681.3M1.1B759M554.5M
Net Receivables132K1.7M745M43M42M39.9M
Common Stock Shares Outstanding43.8M54.8M74.0M72M74M57.8M
Short Term Investments130.3M555.2M351.4M803M632M380.7M
Liabilities And Stockholders Equity203.1M772.3M1.6B1.3B1.1B767.6M
Non Current Liabilities Total16.6M148.3M584.4M495M449M239.9M
Capital Surpluse357.9M369.1M830.4M1.1B1.3B1.4B
Other Current Assets4.3M1M16M15M30M31.5M
Other Stockholder Equity369.1M830.4M1.1B(7M)(8.1M)(7.6M)
Total Liab39.3M270.0M750.4M688M633M339.3M
Long Term Investments0.06.4M182.0M129M107M59.2M
Property Plant And Equipment Gross9.3M10.8M155.2M58M82M47.6M
Total Current Assets192.7M735.1M681.3M1.1B831M555.9M
Accumulated Other Comprehensive Income64K44K(1.3M)(7M)(6.3M)(6.0M)
Non Current Liabilities Other806K148.3M584.4M140M142M140.0M
Property Plant Equipment9.3M10.8M32.5M135M155.3M163.0M
Current Deferred Revenue7M74.6M102.0M97M91M60.2M
Deferred Long Term Liab15.8M3.2M4M3M2.7M2.6M
Net Invested Capital163.8M502.3M841.5M657M462M473.8M
Net Working Capital170.0M614.1M1.1B874M647M598.2M
Short Term Debt9.5M27.9M53.8M3M11M18.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arcus Stock Analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.